Table 2 Summary of number of participants at primary vaccination included in the analysis by treatment arm and reference study.
Age group | Arm | Study assessing the primary dose | Study assessing the persistence data | N | T1 n (%) | T2 n (%) | T3 n (%) |
|---|---|---|---|---|---|---|---|
Adolescents/young adults | MenACYW-TT | Dhingra et al. (NCT02842853)28 | Zambrano et al. (NCT04084769)26 | 139 | 137 (98.6%) | 137 (98.6%) | N/A |
Adolescents/young adults | MenACYW-TT | Chang et al. (NCT02199691)27 | 241 | 239 (99.2%) | 239 (99.2%) | N/A | |
Adolescents/young adults | MenACWY-CRM | Dhingra et al. (NCT02842853)28 | 56 | 3 (5.6%) | 3 (5.6%) | N/A | |
Adolescents/young adults | MenACWY-CRM | Chang et al. (NCT02199691)27 | 134 | 132 (98.5%) | 132 (98.5%) | N/A | |
Older adults | MPSV4 | Kirstein et al. (NCT01732627)33 | 26 | 26 (100.0%) | 26 (100.0%) | N/A | |
Older adults | MPSV4 | Esteves-Jarmillo et al. (NCT02842866)32 | 170 | 168 (98.8%) | 168 (98.8%) | 23 (13.5%) | |
Older adults | MenACYW-TT | Kirstein et al. (NCT01732627)33 | 60 | 58 (96.7%) | 58 (96.7%) | N/A | |
Older adults | MenACYW-TT | Esteves-Jarmillo et al. (NCT02842866)32 | 215 | 212 (98.6%) | 212 (98.6%) | 28 (13.0%) | |
Toddlers | MenACYW-TT | Van der Vilet et al. (NCT02955797)35 | Martinón-Torres et al. (NCT04936685)34 | 208 | 208 (100.0%) | 208 (100.0%) | N/A |
Toddlers | MenACYW-TT | Vesikari et al. (NCT00427908)25 | Piazza et al. (NCT03476135)22 | 42 | 42 (100.0%) | 42 (100.0%) | N/A |
Toddlers | MCV4-TT | Vesikari et al. (NCT00427908)25 | 49 | 49 (100.0%) | 49 (100.0%) | N/A |
